^
Association details:
| Biomarker: | IL17C-L |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Elrexfio (elranatamab-bcmm) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.
Published date:
05/25/2023
Excerpt:
In MagnetisMM-3, patients received subcutaneous elranatamab in 28-day cycles with step-up doses of 12 mg on C1D1 and 32 mg on C1D4 followed by 76 mg QW beginning C1D8....Baseline levels of IL-6 (2.6-fold), IL-17C (2.0-fold), and MIP-1α (2.1-fold) were lower in patients who achieved a response.
DOI:
10.1200/JCO.2023.41.16_suppl.8044
Trial ID:
Source:
Title:
IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A
Published date:
05/11/2023
Excerpt:
In MagnetisMM-3, patients received subcutaneous elranatamab in 28-day cycles with step-up doses of 12 mg onC1D1 and 32 mg on C1D4 followed by 76 mg QW beginning C1D8….Baseline levels of IL-6 (2.6-fold), IL-17C (2.0-fold), and MIP-1α (2.1-fold) were lower in patients who achieved a response.
Trial ID:
